DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Bristol Myers Squibb

Bristol Myers Squibb

  • Print Layout 1

    Print Layout 1

  • Faculty Disclosure

    Faculty Disclosure

  • Ipo Virtual Annual Meeting Sept

    Ipo Virtual Annual Meeting Sept

  • Bristol Myers

    Bristol Myers

  • Investor Presentation March 19, 2019

    Investor Presentation March 19, 2019

  • FDA Listing of Authorized Generics As of July 1, 2021

    FDA Listing of Authorized Generics As of July 1, 2021

  • Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grants Request for Educational Support (RFE)

    Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grants Request for Educational Support (RFE)

  • 1 2 3 4 5 6 7 8 ABCDEFG First Name Last Name

    1 2 3 4 5 6 7 8 ABCDEFG First Name Last Name

  • Op0227 Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active Psoriatic Arthritis

    Op0227 Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active Psoriatic Arthritis

  • Johnson & Johnson Qui Tam Relators Complaint

    Johnson & Johnson Qui Tam Relators Complaint

  • Ddurie@Durietangri.Com Steve@Hilliardshadowenlaw.Com MARK A

    [email protected] [email protected] MARK A

  • Sign-Up Form for the Bristol-Myers Squibb Patient Assistance Foundation

    Sign-Up Form for the Bristol-Myers Squibb Patient Assistance Foundation

  • Bristol-Myers Squibb and Gilead Sciences, LLC 1 • Hepatic Impairment: ATRIPLA Is Not Recommended for Patients with Moderate Or Severe Hepatic Impairment

    Bristol-Myers Squibb and Gilead Sciences, LLC 1 • Hepatic Impairment: ATRIPLA Is Not Recommended for Patients with Moderate Or Severe Hepatic Impairment

  • Abbvie Proves the Best at Getting the Most out of Its Workers

    Abbvie Proves the Best at Getting the Most out of Its Workers

  • Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grants Request for Educational Support (RFE)

    Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grants Request for Educational Support (RFE)

  • Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

    Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

  • Linlin Luo, Ph.D. Large Pharma Merck & Co. Myers Squibb

    Linlin Luo, Ph.D. Large Pharma Merck & Co. Myers Squibb

  • Lilly, Roche, Merck & Co, Astrazeneca, Wyeth, Bristol-Myers

    Lilly, Roche, Merck & Co, Astrazeneca, Wyeth, Bristol-Myers

Top View
  • Bristol Myers Squibb J.P. Morgan 2021 Presentation
  • Alzheimer's Disease
  • 05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D051 Page: 01
  • Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis
  • 1 Case 4:08-Cv-02920-BRW Document 12 Filed 01/29/13 Page 1 of 13
  • Incoming Letter: Danaher Corporation
  • 2020-21 BMS Pharmd Fellowship Program
  • EISAI and BRISTOL MYERS SQUIBB ENTER INTO GLOBAL STRATEGIC COLLABORATION for EISAI’S Morab-202 ANTIBODY DRUG CONJUGATE
  • Faculty Disclosures
  • MED-Project Participating Drug Companies - King County Washington, March 2020
  • Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect® MM Registry
  • Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies Relapsed Or Refractory Multiple Myeloma Regardless of Patient Age: Da
  • Top 10 Best-Selling Drugs of 2019
  • More- Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS™ Real-World Data Program Grows to Sample Size of Nearly One Million Live
  • Senate Pharmaceutical Industry Financial Holdings, 2004
  • Principles of Integrity
  • Faculty Disclosures
  • 1288.Full.Pdf


© 2024 Docslib.org    Feedback